Bank of America Securities analyst Sachin Jain has reiterated their bullish stance on SNYNF stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sachin Jain has given his Buy rating due to a combination of factors including Sanofi’s strong sales performance and promising growth prospects. The company reported a 5% year-over-year increase in sales, reaching EUR 9.9 billion, which aligns with market expectations. Although the earnings per share (EPS) fell slightly below consensus due to increased R&D spending, this is expected to be a temporary setback.
Furthermore, Sanofi’s key product, Dupixent, showed a 12% year-over-year growth, driven by its launch for COPD treatment, which is expected to accelerate further. Other products like Altuviiio and Lantus also demonstrated robust growth, contributing to the overall positive outlook. Despite some challenges with foreign exchange impacts, Sanofi’s strategic focus on product innovation and efficiency improvements supports the Buy rating.